Med Tech-related technology assessments from NICE in July 2024

The National Institute for Health and Care Excellence (NICE) Diagnostic Guidance (DG) program focuses on evaluating innovative medical diagnostic technologies to ensure that the NHS can adopt clinically and cost-effective technologies rapidly and consistently.

In July 2024, NICE published one new DG, which recommended CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack. NICE also made specific recommendations for lab-based and point-of-care tests (POCT):

• Laboratory-based testing for CYP2C19 genotype testing is considered a first-line;
• Genedrive CYP2C19 ID Kit POCT for CYP2C19 genotype testing should be used when laboratory-based testing is not available;
• Genomadix Cube POCT should be used when laboratory-based testing and the Genedrive CYP2C19 ID Kit POCT are not available.

Technology Appraisal is the only NICE program that has a direct link with payers' acceptance of technologies. Payers need to implement the recommended technologies within three months after the publication of the guidance. Medical devices are very rarely evaluated within the Technology Appraisal program.

In July 2024, NICE released Technology Appraisal Guidance on selective internal radiation therapy (SIRT) with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma. NICE recommended SIRT with QuiremSpheres as an option for treating unresectable advanced hepatocellular carcinoma in adults only if it is used for people with Child-Pugh grade A liver impairment when conventional transarterial therapies are inappropriate, and the company provides it according to the commercial arrangement.

No new or updated clinical guidelines were published by NICE in July 2024.

See the full details here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.